{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:17:51Z","timestamp":1791379071306,"version":"4.3.2"},"reference-count":34,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objectives\nEvaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD).\nMethods\n10-week (8-week active-treatment\/2-week post-treatment), randomized, double-blind, placebo- and active-controlled study (D1448C00004). Patients received quetiapine XR 150 mg\/day, escitalopram 10 mg\/day, or placebo; patients with an inadequate response (<\/jats:p>","DOI":"10.64719\/pb.4057","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"5-30","source":"Crossref","is-referenced-by-count":0,"title":["A Randomized, Double-blind Study of the Efficacy and Tolerability of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients with Major Depressive Disorder"],"prefix":"10.64719","volume":"45","author":[{"given":"Gang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie R.","family":"Earley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Raines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25:2289\u20132304.","DOI":"10.1016\/S0149-2918(03)80220-5"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Howland RH. Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv. 2008;46:21\u201324.","DOI":"10.3928\/02793695-20081001-05"},{"key":"ref3","unstructured":"AstraZeneca. Seroquel XR\u2014Summary of Product Characteristics for Ireland. Available at: http:\/\/www.medicines.ie\/medicine\/13032\/SPC\/Seroquel+XR150mg%2c1+50mg%2c+200mg%2c+300mg%2c+400mg+prolonged-release+tablets\/ Accessed: 11\/14\/2011."},{"key":"ref4","unstructured":"AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets\/US prescribing information. Available at: http:\/\/www1.astrazeneca-us.com\/pi\/seroquelxr.pdf Accessed: 11\/14\/2011."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011;128:83\u201394.","DOI":"10.1016\/j.jad.2010.06.031"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cutler AJ, Montgomery SA, Feifel D et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009;70:526\u2013539.","DOI":"10.4088\/JCP.08m04592"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Weisler R, Joyce M, McGill L et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14:299\u2013313.","DOI":"10.1017\/S1092852900020307"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Bauer M, Pretorius HW, Constant EL et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540\u2013549.","DOI":"10.4088\/JCP.08m04629"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"El-Khalili N, Joyce M, Atkinson S et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13:917\u2013932.","DOI":"10.1017\/S1461145710000015"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Liebowitz M, Lam RW, Lepola U et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27:964\u2013976.","DOI":"10.1002\/da.20740"},{"key":"ref11","unstructured":"Katila H, Mezhebovsky I, Mulroy A et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. In press."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Glick ID, Suppes T, DeBattista C et al. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Ann Intern Med. 2001;134:47\u201360.","DOI":"10.7326\/0003-4819-134-1-200101020-00013"},{"key":"ref13","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 (Suppl 20):22\u201333."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","DOI":"10.1136\/jnnp.23.1.56"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Montgomery SA, \u00c5sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u2013389.","DOI":"10.1192\/bjp.134.4.382"},{"key":"ref16","unstructured":"Forest Pharmaceuticals, Inc. Escitalopram prescribing information. Available at: http:\/\/www.frx.com\/pi\/lexapro_pi.pdf Accessed: 5\/1\/2011."},{"key":"ref17","unstructured":"National Institutes of Mental Health. CGI: Clinical Global Impressions. Guy W, Bonato RR. Manual for the ECDEU Assessment Battery. 1970:1\u20136. Chevy Chase: NIMH."},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u201355.","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Endicott J, Nee J, Harrison W et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321\u2013326.","DOI":"10.1037\/t49981-000"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Buysse DJ, Reynolds CF, III, Monk TH et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193\u2013213.","DOI":"10.1016\/0165-1781(89)90047-4"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u201319.","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u2013676.","DOI":"10.1192\/bjp.154.5.672"},{"key":"ref23","unstructured":"Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33:731\u2013745."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Michelson D, Fava M, Amsterdam J et al. Interruption of selective serotonin reuptake inhibitor treatment Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363\u2013368.","DOI":"10.1192\/bjp.176.4.363"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Rosenbaum JF, Fava M, Hoog SL et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77\u201387.","DOI":"10.1016\/S0006-3223(98)00126-7"},{"key":"ref26","unstructured":"Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol. 2005;6:221\u2013226."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem. 2005;5:1077\u20131086.","DOI":"10.2174\/156802605774297092"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Fava M, Evins AE, Dorer DJ et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115\u2013127.","DOI":"10.1159\/000069738"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kobak KA, Kane JM, Thase ME et al. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol. 2007;27:1\u20135.","DOI":"10.1097\/JCP.0b013e31802eb4b7"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009;19:34\u201340.","DOI":"10.1016\/j.euroneuro.2008.08.009"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Posternak MA, Zimmerman M, Keitner GI et al. A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry. 2002;159:191\u2013200.","DOI":"10.1176\/appi.ajp.159.2.191"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Stein DJ, Baldwin DS, Dolberg OT et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67:1741\u20131746.","DOI":"10.4088\/JCP.v67n1111"},{"key":"ref33","unstructured":"FDA. Antidepressant use in children, adolescents and adults. Available at: http:\/\/www.fda.gov\/cder\/drug\/antidepressants\/default.htm Accessed: 5\/1\/2011."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596\u2013601.","DOI":"10.2337\/diacare.27.2.596"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:24:15Z","timestamp":1791314655000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/a-randomized-double-blind-study-of-the-efficacy-and-tolerability-of-extended-release-quetiapine-fumarate-quetiapine-xr-monotherapy-in-patients-with-major-depressive-disorder\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4057","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}